Chemistry: molecular biology and microbiology – Differentiated tissue or organ other than blood – per se – or... – Including perfusion; composition therefor
Patent
1990-07-24
1993-07-27
Robinson, Douglas W.
Chemistry: molecular biology and microbiology
Differentiated tissue or organ other than blood, per se, or...
Including perfusion; composition therefor
514474, 514659, A01N 102, A01N 4308, A01N 3302
Patent
active
052309967
ABSTRACT:
A method and pharmaceutical agent are provided for the prevention and treatment of cardiovascular disease, particularly cardiovascular disease in the context of diabetic angiopathy, by-pass surgery, organ transplantation, and hemodialysis, by administering ascorbate and substances that inhibit the binding of lipoprotein (a) to blood vessel walls. The use of ascorbate and lipoprotein (a) binding inhibitors such as tranexamic acid in a temporary storage solution for blood vessels and organs prior to transplantation is also demonstrated.
REFERENCES:
patent: 4443546 (1984-04-01), Stemerman
Krystal, G, Arthritis Rheum. 25:318-25 (1982).
Kurokawa, Y, Tohoku J. Ex. Med. 134:183-93 (1981).
Feng, J., In Vitro 13:91-99 (1977).
Malemud, C, Connect Tissue Res 6:171-9 (1978).
Hinrichs U, Arzneimittelforschung 33:143-9 (1983).
Risley, M, Biol Reprod. 36:985-97 (1987).
Popov I, Z. Exp. Chir. Transplant Kunstliche Organe 22:22-6 (1989).
Schiff, L, In Vitro 16:893-906 (1980).
Vinograd-Finkel, F, Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 49:264 (1972).
Rath, M. & L. Pauling, "Solution of the puzzle of human cardiovascular disease: Its primary cause is ascorbate deficiency, leading to the deposition of lipoprotein(a) and fibrinogen/fibrin in the vascular wall," J. Orthomolecular Med. (In Press 1991).
Markwardt, F. & H. P. Klocking, "Chemical control of hyperfibrinolytic states by synthetic inhibitors of fibrinolytic enzymes," Biomed. Biochim. Acta 42:725-730 (1983).
Werb, Z. et al., "Endogenous activation of latent collagenase by rheumatoid synovial cells," New England J. Med 296(18):1017-1023 (1977).
Knox, E. G., "Ischaemic-heart-disease mortality and dietary intake of calcium," Lancet, i, pp. 1465-1467, Jun. 30, 1973.
Berg, K. "A new serum type system in man--The Lp system," Acta Path. 59:369-382 (1963).
McLean, J. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen," Nature 300:132-137 (1987).
Salonen, E-M, et al., "Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it," EMBO J. 8(13):4035-4040 (1989).
Harpel, P. C. et al., "Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin," Proc. Natl. Acad. Sci. USA 86:3847-3851 (1989).
Gonzalez-Gronow, M. et al., "Further characterization of the cellular plasminogen biding site: Evidence that Plasminogen 2 and Lipoprotein a compete for the same site," Biochemistry 28:2374-2377 (1989).
Hajjar, K. A. et al., "Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis" Nature 339:303-305 (1989).
Armstrong, V. W. et al., "The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis"; Atherosclerosis 62:249-257 (1986).
Dahlen, G. H., et al., "Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography," Circulation 74(4):758-765 (1986).
Miles, L. A. et al., "A potential basis for the thrombotic risks associated with Lipoprotein (a)," Nature 339:301-302 (1989).
Zenker, G. et al., "Lipoprotein(a) as a strong indicator for cerebrovascular disease," Stroke 17(5)942-945 (1986).
Zechner, R. et al., "Fluctuations of plasma Lipoprotein-A concentrations during pregnancy and post partum," Metabolism 35(4):333-336 (1986).
Hoff, H. et al., "Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients," Circulation 77(6):1238-1244 (1988).
Rath, M. et al., "Detection and quantification of Lipoprotein(a) in the arterial wall of 107 coronary bypass patients," Arteriosclerosis 9(5):579-592 (1989).
Cushing, G. L. et al., "Quantitation and localization of Apolipoproteins [a] and B in Coronary artery bypass vein grafts resected at re-operation," Arteriosclerosis 9(5):593-603 (1989).
Bruckert, E. et al., "Increased serum levels of Lipoprotein(a) in diabetes mellitus and their reduction with glycemic control," JAMA 263(1):35-36 (1990).
Blumberg, B., et al., "A human lipoprotein polymorphism," J. Clin. Invest. 41:1936-1944 (1962).
Eaton, D. L., et al., "Partial amoni acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen," Proc. Natl. Acad. Sci. USA, 84:3224-3228 (1987).
Wright, L. C. et al., "Elevated apolipoprotein(a) levels in cancer patients," Int. J. Cancer 43:241-244 (1989).
Som, S. et al., "Ascorbic acid metabolism in diabetes mellitus," Metabolism 30:572-577 (1981).
Maeda, S. et al., "Transient changes in serum liproprotein(a) as an acute phase protein," Atherosclerosis 78:145-150 (1989).
Kapeghian, J. C. et al., "The effects of glucose on ascorbic acid uptake in heart endothelial cells: Possible pathogenesis of diabetic angiopathies," Life Sci. 34:577 (1984).
Tomlinson, J. E. et al., "Rhesus monkey apolipoprotein(a," J. Biol. Chem. 264:5957-5965 (1989).
Ginter, E. et al., "The effect of chronic hypovitaminosis C on the metabolism of cholesterol and athergenesis in guinea pigs," J. Atherosclerosis Res. 10:341-352 (1969).
Pauling Linus C.
Rath Matthias W.
Limbach George C.
Robinson Douglas W.
Saucier S.
Therapy 2000
LandOfFree
Use of ascorbate and tranexamic acid solution for organ and bloo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ascorbate and tranexamic acid solution for organ and bloo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ascorbate and tranexamic acid solution for organ and bloo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2341725